A novel drug, linzagolix, has shown remarkable effectiveness in reducing moderate to severe endometriosis-associated pain in phase 3 clinical trials, with a favorable safety profile and minimal side effects.
Endometriosis is a chronic inflammatory condition affecting the female reproductive system, where tissue similar to the uterine lining grows outside the uterus. This ectopic tissue responds to hormonal changes, thickening and bleeding during the menstrual cycle, often invading nearby organs. The exact causes remain under investigation, but it impacts about 10% of French women of childbearing age. Symptoms include pelvic pain during menstruation or intercourse, and in some cases, infertility, significantly affecting quality of life both personally and professionally.
Currently, no curative treatment exists. Available options are ineffective for many and carry risks like bone density loss, hot flashes, insomnia, and mood alterations. Promising developments, however, may change this landscape.
Linzagolix, an experimental therapy from biopharmaceutical company ObsEva, is under evaluation for managing endometriosis-related pain and heavy menstrual bleeding from uterine fibroids.
Late 2021 phase 3 trial results were compelling enough for the U.S. FDA to consider linzagolix for uterine fibroids. Approval for endometriosis pain relief could follow soon.
The trials tested two oral doses: 200 mg daily (with add-on hormone therapy) and 75 mg daily (without, for those unable or unwilling to use add-on therapy). Linzagolix reduces ovarian estrogen production, hence the add-on for the higher dose.
Both doses significantly outperformed placebo in reducing menstrual cramps, dyschezia, and non-menstrual pelvic pain after three months, with benefits sustained up to six months.
In phase 2b trials, hot flashes were the most frequent side effect, affecting 20% of women on 75 mg and nearly half on 200 mg. The lower dose showed no clinically meaningful impact on bone mineral density, while only minimal loss occurred with the higher dose.
"Although recent advances have improved non-surgical options for endometriosis, effective treatments remain critically needed," notes Hugh S. Taylor, MD, Chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine and trial lead. "Once-daily linzagolix 200 mg with add-on therapy showed excellent efficacy and minimal bone mineral density changes, supporting its potential for long-term use."
Note: These results are preliminary and not yet peer-reviewed; interpret with caution.
